Microdosing of LSD does not show efficacy in adults with ADHD
The Brown University Psychopharmacology Update July 1, 2025 Peer reviewed DOI: 10.1002/pu.31324
Summary
Microdosing of LSD for 6 weeks did not show significant benefits compared to placebo in reducing ADHD symptoms in adults. Both groups, however, experienced notable improvements.
Study at a glance
| Design | Phase 2A trial |
|---|---|
| Population | adults with attention-deficit hyperactivity disorder (ADHD) |
| Key finding | Microdosing of LSD showed no significant benefits over placebo for ADHD symptoms. |
Abstract
Microdosing of lysergic acid diethylamide (LSD) over a 6‐week period showed no significant benefits over placebo in reducing symptoms of attention‐deficit hyperactivity disorder (ADHD) in adults, a Phase 2A trial has found. Both the LSD and placebo groups experienced marked improvement, the investigators reported.